Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.4K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.4K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.3K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of glaucoma as a neurodegenerative disease.

Neurodegenerative disease management·2026
Same author

Correction: Yap et al. Real-Time Imaging of Retinal Ganglion Cell Apoptosis. <i>Cells</i> 2018, <i>7,</i> 60.

Cells·2025
Same author

Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study.

The British journal of ophthalmology·2025
Same author

The Effects of the COVID-19 Pandemic on the Follow-Up of Patients with Age-Related Macular Degeneration in a Tertiary Hospital in London, the UK.

Journal of clinical medicine·2025
Same author

Minimally Invasive Tube Surgery (MITS)-A Novel Method in Glaucoma Drainage Device Implantation.

Journal of clinical medicine·2024
Same author

Review: Neuroprotective Nanocarriers in Glaucoma.

Pharmaceuticals (Basel, Switzerland)·2024
Same journal

RETRACTED: Kim et al. The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Regulating the Visceral Adipose-Tissue Function. <i>Int. J. Mol. Sci.</i> 2017, <i>18</i>, 846.

International journal of molecular sciences·2026
Same journal

Correction: Mahmud et al. Thymoquinone Attenuates NF-κβ Signalling Activation in Retinal Pigment Epithelium Cells Under AMD-Mimicking Conditions. <i>Int. J. Mol. Sci.</i> 2025, <i>26</i>, 11473.

International journal of molecular sciences·2026
Same journal

Correction: Borovikov et al. The Twisting and Untwisting of Actin and Tropomyosin Filaments Are Involved in the Molecular Mechanisms of Muscle Contraction, and Their Disruption Can Result in Muscle Disorders. <i>Int. J. Mol. Sci</i>. 2025, <i>26</i>, 6705.

International journal of molecular sciences·2026
Same journal

Correction: Molagoda et al. Flavonoid Glycosides from <i>Ziziphus jujuba</i> var. <i>inermis</i> (Bunge) Rehder Seeds Inhibit α-Melanocyte-Stimulating Hormone-Mediated Melanogenesis. <i>Int. J. Mol. Sci.</i> 2021, <i>22</i>, 7701.

International journal of molecular sciences·2026
Same journal

Correction: Guo et al. Integrated Transcriptomic and Metabolomic Analysis Reveals the Molecular Regulatory Mechanism of Flavonoid Biosynthesis in Maize Roots Under Lead Stress. <i>Int. J. Mol. Sci.</i> 2024, <i>25</i>, 6050.

International journal of molecular sciences·2026
Same journal

Correction: Chang et al. Improvement of Carbon Tetrachloride-Induced Acute Hepatic Failure by Transplantation of Induced Pluripotent Stem Cells Without Reprogramming Factor c-Myc. <i>Int. J. Mol. Sci.</i> 2012, <i>13</i>, 3598-3617.

International journal of molecular sciences·2026
See all related articles

Related Experiment Video

Updated: Feb 11, 2026

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.7K

Annexins in Glaucoma.

Timothy E Yap1,2, Benjamin Michael Davis3, Li Guo4

  • 1The Western Eye Hospital, Imperial College Healthcare NHS Trust (ICHNT), London NW1 5QH, UK. timothyedward.yap@nhs.net.

International Journal of Molecular Sciences
|April 21, 2018
PubMed
Summary
This summary is machine-generated.

Glaucoma, a leading cause of blindness, affects millions. The DARC project uses Annexin A5 to detect retinal cell apoptosis, aiding in diagnosis and treatment research for this condition.

Keywords:
annexinapoptosisglaucomaimagingneurodegenerationretinal ganglion cell

More Related Videos

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.9K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K

Related Experiment Videos

Last Updated: Feb 11, 2026

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.7K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.9K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Cell Biology

Background:

  • Glaucoma is a primary cause of irreversible vision loss, impacting millions globally and necessitating improved diagnostic and therapeutic strategies.
  • Annexin A5, a protein binding phosphatidylserine on apoptotic cells, is a key indicator of cellular death.
  • Retinal ganglion cell apoptosis is a hallmark of glaucomatous neurodegeneration.

Purpose of the Study:

  • To summarize the application of Annexin A5 as an apoptosis marker in ocular diseases.
  • To present the advancements of the DARC (Detection of Apoptosing Retinal Cells) project in imaging retinal apoptosis.
  • To explore the potential of DARC as a biomarker for neurodegenerative conditions and glaucoma.

Main Methods:

  • Utilizing fluorescently-labeled Annexin A5 for the detection of apoptosis.
  • Developing real-time in vivo imaging techniques for retinal ganglion cell apoptosis.
  • Investigating mechanisms of neurodegeneration and potential treatments.

Main Results:

  • Demonstrated the utility of Annexin A5 in assessing glaucomatous degeneration.
  • Advanced DARC project capabilities for in vivo imaging of retinal apoptosis in disease models.
  • Initiated first human clinical trials applying DARC technology.

Conclusions:

  • Annexin A5 is a valuable marker for ocular apoptosis.
  • The DARC project shows promise for real-time monitoring of neurodegeneration.
  • DARC technology has potential as a diagnostic and monitoring tool for glaucoma and other neurodegenerative diseases.